The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.
The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.
The company’s latest report states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) three monoclonal antibodies (mAbs), all PCSK9 inhibitors, have the potential to reshape the post-ACS, dyslipidemia landscape.
Amgen’s evolocumab, Sanofi and Regeneron’s alirocumab, and Pfizer’s bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, it is reported; it is expected that these treatments to be launched in the middle of the forecast period. GlobalData’s Eric J. Dimise, Ph.D, forecasts that these treatments “will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion.”
GlobalData has also identified two new anticoagulants, Janssen’s Xarelto and Merck’s Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years.
Dimise states that Xarelto, when approved for the ACS indication in the US by 2018, will result in peak-year sales approaching $8 billion for ACS alone, while Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.